This meta-analysis provides robust evidence that pembrolizumab significantly improves overall survival, progression-free survival, and objective response rates in patients with advanced non-small cell lung cancer exhibiting PD-L1-positive expression. Here, CD274 is linked to non-small cell lung carcinoma.